CSL strikes $1.55B lixudebart deal with Alentis for rare kidney and liver diseases
CSL (CSLLY) and Alentis Therapeutics have entered an exclusive global partnership to co-develop and co-promote lixudebart for rare kidney, liver, and other diseases.
Under the agreement, CSL (CSL) will arrange an initial payment of $355M to Alentis, which is also eligible
KioskNews shows a cleaned-up reading view extracted from the publisher’s page — the original always lives on their site, not ours.